How HLA Humanized Mice Are Transforming Preclinical Research and Immunotherapy
December 13, 2024
How does the immune system distinguish friend from foe? Human Leukocyte Antigens (HLAs) are key players in this process, acting as molecular “spotlights” that present peptide antigens to immune cells, triggering antibody production and the elimination of abnormal cells. HLA molecules are classified into two types: HLA Class I: Expressed on nearly all nucleated cells, […]
The Future of Cancer Treatment: Cutting-Edge Advances in Immuno-Oncology
November 8, 2024
Imagine a future where cancer treatment is as precise and personalized as it is powerful, where the body’s own defenses are guided to hunt down and destroy tumors. This vision is becoming reality through immuno-oncology (IO), a transformative field empowering the immune system to selectively attack cancer cells. Unlike traditional treatments like chemotherapy and radiation, […]
Breaking Down Barriers in Drug Development: Key Takeaways from Biocytogen’s Maryland Forum
November 5, 2024
One of the biggest challenges in personalized medicine is not only proving efficacy but also ensuring feasible manufacturing at scale. Unlike traditional therapies developed for broader populations, personalized treatments are tailored for individuals, raising complex questions in CMC (Chemistry, Manufacturing, and Controls). How can production be controlled and scaled for drugs designed for individual patients? […]
GSK’s $300M Acquisition of Chimagen’s CMG1A46: A Deep Dive into B Cell-Targeted Trispecific T Cell Engagers
November 4, 2024
On October 29, GSK made headlines with a $300 million upfront payment to acquire Chimagen Biosciences’ clinical-stage asset, CMG1A46, a dual-target CD19/CD20 trispecific T cell engager (TCE). This acquisition signals GSK’s commitment to advancing therapies for B-cell-driven autoimmune diseases, such as systemic lupus erythematosus and lupus nephritis, with possible applications in other autoimmune conditions. B […]
Breaking the Diabesity Cycle: Unveiling New Research on Obesity and Diabetes
October 17, 2024
Obesity and diabetes are two of the most pressing health challenges facing society today, impacting millions and often occurring hand in hand. As obesity rates have soared to epidemic levels, Type 2 diabetes has followed suit. While researchers have long known of this connection, only recently have they begun to uncover the complex mechanisms linking […]
Meet Biocytogen at Bio-Europe 2024!
October 15, 2024
Biocytogen (HKEX: 02315) is excited to attend Bio-Europe 2024 in Stockholm, Sweden, from November 4-6! Our Business Development Team is excited to meet you in person at Booth #74! Schedule a 1-on-1 meeting with us, and stop by to discover our innovative solutions in antibody drug discovery! RenBiologics – Our fully human library. Your pipeline. Developed using our […]
Unlocking the Autism Puzzle: Genes, Minds, and Untold Possibilities
October 4, 2024
Autism Spectrum Disorder (ASD), often identified in early childhood, presents challenges in social interactions, communication, and repetitive behaviors. The term “spectrum” reflects the wide range of abilities, with some individuals displaying exceptional skills, while others face significant difficulties, such as non-verbal communication, aggression, epilepsy, and self-injury. Sometimes referred to as “children of the stars,” individuals […]
The Blood-Brain Barrier: A Double-Edged Sword in Neurology
September 17, 2024
The brain, our most intricate and vital organ, is safeguarded by a unique structure known as the blood-brain barrier (BBB). Acting as a fortress, the BBB keeps harmful substances out while preserving the delicate environment of the brain. This protective mechanism, however, also poses significant challenges in developing drugs for the central nervous system (CNS). […]
Charting New Frontiers in GvHD Treatment: Insights from Niktimvo™ FDA approval
September 4, 2024
On August 14, 2024, Syndax and Incyte announced the FDA approval of Niktimvo™ (axatilimab-csfr), a CSF-1R monoclonal antibody, for the treatment of chronic graft-versus-host disease (GvHD). Axatilimab is the first CSF-1R monoclonal antibody to receive approval, specifically targeting the drivers of inflammation and fibrosis in chronic GvHD (Business Wire, 2024). CSF-1R, a cell surface protein, […]
Conquering the Inner Struggle: Mastering Autoimmune and Inflammatory Diseases
August 15, 2024
It’s well-known that a robust immune system is fundamental to good health. Yet, did you know that our immune system, designed to protect us, can sometimes turn against us, attacking the body itself? This troubling issue lies at the heart of autoimmune diseases. In these conditions, the immune system mistakenly targets healthy tissues, causing inflammation […]
